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A B S T R AC T This study examines the perspectives of psychotropic medications
held by young adults with mood disorder diagnoses. This article presents an analy-
sis of qualitative interviews with 52 young adults who had been involved with
public systems of care during adolescence and had used psychiatric medications. A
concatenated analytic approach was used. First, we used a thematic analysis across
cases, then a narrative analysis within selected cases. Two main themes emerged
from the thematic analysis that captured aspects of the experience of taking medi-
cation. First, young adults described the effects of the medications and how they
thought the medications were working. They described the impact on their moods,
thinking, bodies, and functioning, and the ways in which these effects related to
their lives. Second, the process of taking medications emerged as an important
aspect of the medication treatment experience, including the trial-and-error nature
of treatment and interactions with psychiatrists. The narrative analysis within cases
identified that some youth created a medication narrative composed of three ele-
ments: why medications were needed, what medications do, and participants’ out-
look on future medication use. These narratives are helpful in understanding prior
patterns of service use and are instructive in framing young people’s future inten-
tions to use medications. Findings support the importance of eliciting the perspec-
tives of young adults about their treatment and ensuring that services are designed
and delivered in developmentally appropriate ways tailored to this group.




dolescents served in public systems of care such as the juvenile justice
and child welfare systems have elevated rates of mood disorders as com-
pared with their peers in the general population (Garland et al., 2001;
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Keller, Salazar, & Courtney, 2010; McMillen et al., 2005; Merikangas et al., 2010;
Teplin, Abram, McClelland, Dulcan, & Mericle, 2002) and are thus at elevated
risk for mental health problems in young adulthood (Copeland et al., 2013). In a
longitudinal study of youth with a mental disorder who were involved in juve-
nile detention, approximately 1 in 5 youth continued to experience symptoms
from adolescence into adulthood (Teplin, Welty, Abram, Dulcan, & Washburn,
2012). Psychotropic medications are often a central part of treatment for mood
disorders in adolescents (i.e., Bowden et al., 2012; Crismon & Argo, 2009; Gaynes
et al., 2009; Rush, 2011), yet many youth involved in public systems stop us-
ing medications in young adulthood after they leave these systems (McMillen
& Raghavan, 2009). Although some evidence has suggested these young adults
choose to discontinue medication treatment (McMillen & Raghavan, 2009), little
of the available evidence is helpful toward understanding how these young
adults experience medication treatment and why they decide to continue or dis-
continue treatment. Prior studies have emphasized the importance of under-
standing the process and experience of taking medications beyond the physical
effects, and researchers have recommended further exploration in specific popu-
lations (i.e., Davis-Berman & Pestello, 2008; Moses, 2008). To better understand
the subjective experiences of young adults taking medications and their decision-
making process when choosing to continue or discontinue medications in young
adulthood, we explored the perspectives toward psychotropic medications of
young adults with mental health diagnoses who have transitioned out of public
systems of care.
Why Focus on Young Adults Involved With Public Systems of Care?
Our focus on the medication experiences of young people who have transitioned
out of public systems of care was driven by several factors. First, youth in the
child welfare system have high rates of both psychotropic medication treatment
(i.e., Raghavan et al., 2005; Rubin et al., 2012) and polypharmacy (i.e., dosReis
et al., 2011; Zito et al., 2008), raising questions about the appropriateness of
treatment these youth have received (McMillen & Fedoravicius, 2007). Over their
time in the system, some young people have received multiple diagnoses and
multiple medications (Narendorf, Bertram, & McMillen, 2011), and have had
treatment experiences that lead them to question whether they actually need
medications when they have the opportunity to decide for themselves. Second,
given the structure of the child welfare and juvenile justice systems, both of
which involve the courts in mandating treatments, youth in the care of these sys-
tems might have experienced treatment as a decision forced upon them rather
than a choice in which they had an active role. Prior work with adolescents has
shown that those who felt coerced to take medications were less likely to re-
port the intention to continue medication treatment when they could decide for
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themselves (Moses, 2011). A third reason for focusing specifically on the views
of young people who have exited public systems is related to the limited support
systems that these youth have as they leave the child serving systems that have
supported them and transition to independent living as young adults (Osgood,
Foster, & Courtney, 2010). Many of these youth rely on support from social
workers and other mental health professionals, making it critical that these
professionals understand how to engage these young people in conversations
about mental health treatment in ways that respect their views and support
their decisions about the role of medications in managing their symptoms.
The Meaning of Psychiatric Medications
Prior work on how people make meaning of their medication treatment has not
only provided a foundation for understanding how people make sense of this
treatment but also offered a lens for examining which elements might be dis-
tinct for young adults at this developmental stage who are leaving public systems.
Anthropological, sociological, and historical studies of illness and medication
treatment have repeatedly demonstrated the importance of illness representa-
tion, or the symbolic constructions (i.e., meaning making) of routine uses of medi-
cation in the illness experience (Applbaum, 2009; Biehl & Moran-Thomas, 2009
Ecks, 2005; Greene, 2004; Healy, 1997; Oldani, 2009; Lakoff, 2005; Rose, 2003;
Rubin, 2007; Whitmarsh, 2009). Studies that have examined the meaning of med-
ication for people taking antipsychotic medications have found that subjective
experiences with medications influence individuals’ decisions to follow treat-
ment recommendations, and can be an important contributor to clinical outcomes
(Awad, Hogan, Voruganti, & Heslegrave, 1995; Awad, Voruganti, Heslegrave, &
Hogan, 1996; Garavan et al., 1998). Bentley’s (2010) study of medication treatment
among adults with serious mental illness in a residential program found a variety
of representations of the role of medication, including medications as a posi-
tive force, a tolerated fact of life, a source of gratitude and triumph over symp-
toms, a prominent part of the story of mental illness, a protection of human-
ness, and an internal and individual experience. Bentley’s work emphasized the
integral nature of medication experiences with the overall experience of manag-
ing a serious mental illness, and highlighted the need for social workers to facili-
tate conversations specifically about the perceived effects and role of medications
in treatment.
Importance of a Developmental Perspective
Prior work on the subjective meaning of medications has largely focused on
adults with serious mental illness who have developed their understandings of
medications over a long history of treatment. Studies with adolescents provide a
contrasting perspective of those who are newly experiencing medication treat-
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ment. One qualitative study of adolescents suggested that adolescents believed
medications helped them with improving behavior, sleep, relationships, and
calming down; further, those beliefs were informed by different sources in their
environment including their doctors, families, peers, and the media (Floersch
et al., 2009). For young adults who are trying to manage mood disorders and
who have recently taken ownership for their own treatment, the perspectives on
the role of medications in their treatment is likely distinct from that of either
adolescents or adults. Theoretical work focused on understanding young adult
service use has stressed the importance of considering multiple contextual fac-
tors, including the structure of the service system, influential social relation-
ships, and the developmental stage of youth who are transitioning into adult
social roles and taking responsibility for their own health and treatment (Mun-
son et al., 2012). The unique situations of youth exiting public systems of care
during this stage of development warrant added attention to understand the
perspectives of these youth regarding medication treatment.
Medication Use Narratives
One way of incorporating the historical and developmental aspects of young
adult medication perspectives is through the analysis of narratives. Narratives
are stories that give meaning to an experience or event by linking motive, ac-
tions, and consequences, and by doing so, narratives can function as guides for
future actions (Garro & Mattingly, 2000). Narratives of specific service use, such
as use of psychotropic medications, can help researchers, scholars, and practition-
ers to better understand how and why people make decisions to use or discon-
tinue services (Bissell, Ryan & Morecroft, 2006). Existing research that has examined
medication narratives in adolescents found the narratives had three components
that answered fundamental questions: Why do I need medication?; What do the
medications do for me?; and How do medications figure into my life in the future?
(Floersch, Longhofer, Kranke, & Townsend, 2010). Young adults exiting public
systems are engaged in a similar process of making meaning of their experi-
ences, yet these experiences are likely to differ substantially from those of adoles-
cents who are living in their family home.
This study used a combined thematic and narrative approach to address sev-
eral gaps in the field’s understanding of young adult perspectives on psychiatric
medication treatment. This article focuses on a group at heightened risk for nega-
tive outcomes: young adults currently struggling with mood and emotional chal-
lenges, all of whom have histories of mood disorder diagnoses and involvement
in public systems of care during childhood and/or adolescence. We examined
qualitative data from both the young adults who chose to continue medication
treatment and those who discontinued taking medications in young adulthood.
We first looked across cases to answer our primary research question: What are
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the experiences with psychotropic medication treatment among young adults
who have exited public systems of care? Then, we looked within cases to ex-
amine the following questions: Do young adults who have left public systems and
are transitioning to adulthood create medication narratives that assist them in
making sense of their experiences of medication treatment? If so, do these medi-
cation narratives help to better understand their decisions and intentions for
medication use as they transition to adulthood?
Method
Sampling and Participants
Participants were recruited as part of a larger study of mental health service use
in the transition to adulthood that was conducted from 2008 to 2010. Potential
participants were recruited through flyers placed at agencies, institutions such as
community colleges, and community locations. Specifically, we were interested in
young people who had used services before their transition to adulthood and
reported ongoing need for services as young adults. Potential participants were
provided with information about the study and screened for inclusion by phone.
Participants met criteria if they had received a diagnosis of a mood disorder
during childhood, used Medicaid-funded mental health services during child-
hood, used one additional public system of care (e.g., child welfare, juvenile jus-
tice, public welfare, special education), and reported currently struggling with
mood and emotional difficulties. Study eligibility on history of service use and
diagnosis was determined using a standardized tool based on screening questions
used in the Diagnostic Interview Schedule (Robins, Cottler, Bucholz, & Comptom,
1995). In addition to these criteria, participants had to respond affirmatively to
the question, “Are you still struggling with mood and emotional difficulties?” We
excluded those currently experiencing psychosis, using illegal/unprescribed sub-
stances, or developmental disability services. Approximately 25% of young adults
who were screened met criteria for study inclusion. All study procedures were
approved by the Human Subjects Review Board and have been described in prior
work (Munson, Scott, Smalling, Kim, & Floersch, 2011).
To focus the current analysis on the use of psychotropic medications, we used a
subset of participants from the larger study. All participants in the current study
(N = 52) were between ages of 18 and 25 years and reported taking psychotropic
medications at some point in their lives. The majority of the sample was female
(71%) and youth of color (68%). Almost all participants reported high levels of
depressive symptoms (96%) but less than half of the sample was currently taking
medications (46%). The most commonly used medications were antidepressants,
although significant percentages were also taking mood stabilizers, anti-psychotics,
and stimulants. Table 1 presents descriptive statistics of the study sample.
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Interview Procedures and Measurement
A semi-structured interview protocol with seven core questions was used to
gather information about mental health service use: (a) “Has your mental health
service use changed since you turned 18?” (b) “How did you transition to services
after turning 18?” (c) “Was there any particular mental health/social service that
you found particularly helpful or not helpful?” (d) Have you run into difficulties
getting mental health services?” (e) “Do you feel you need mental health services
at this time?” (f ) “Do you have the money/resources to pay for them?” (g) “Of all
the reasons not to seek services, why are you not seeking services?” Probes were
used to elicit narratives of service use and to gain additional information. Nota-
bly, interviewers did not ask questions specifically about medication use but
asked about mental health service use broadly.
Participants also responded to several structured instruments. Questions about
past and current medication use and compliance with medications were based
on the Service Assessment for Children and Adolescents (Stiffman, Horwitz, &
Hoagwood, 2000). Participants’ level of depressive symptoms was determined us-
ing the Center for Epidemiological Studies Depression Scale as part of the inter-
view (Locke & Putnam, 1971).
Analytic Strategy
We used a two-stage concatenated approach to analysis. For the first step, we
used a thematic analysis based on grounded theory techniques to explore the
perspectives of our sample toward psychiatric medications. To develop an ini-
tial codebook, we used a constant comparison approach with two analysts
doing line-by-line in vivo coding across five interviews. This codebook was
used to code another 15 interviews and was then refined through discussion to
Table 1
Sample Characteristics (N = 52)




Mood disorder diagnosis in childhood 100 (52)
Current depression (CES-D) 96 (50)
Current psychiatric medication use 46 (24)
Antidepressant 77 (18/24)
Mood stabilizer 46 (11/24)
Antipsychotic 42 (10/24)
Stimulant 29 (7/24)
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create a final version used to code the rest of the interview data. Once all
interviews were coded, analysts engaged in a second round of constant com-
parison, examining content and meaning of the axial codes to derive themes
and dimensions of medication experience. The second step involved a narra-
tive case analysis of the overall story of medication use within cases to answer
our questions about whether young adults constructed medication narratives
and how such narratives influenced their intentions to use services in the
future. We selected the 15 most densely coded cases from the thematic analy-
sis and began a new analysis guided by sensitizing codes from prior work
(Floersch et al., 2010). An iterative process was used to develop and refine the
codebook and code for narratives within cases. We examined these narratives
with a narrow focus on the overall pattern of medication use and its relation
to indications of intentions of future medication use. This article presents case
examples that represent young adults who displayed commitment to medica-
tion treatment, appeared ambivalent about medications, and did not intend to
take medications in the future.
Results
Stage 1: Thematic Analysis
The first stage in the analysis was focused on answering the following question:
What are the experiences of young adults who have exited public systems with
psychotropic medication treatment? To answer this question, we examined all
comments related to psychotropic medications and identified themes based on
the content. Two main themes captured overall experiences with medications:
(a) what medications do to me; (b) what it is like to get medications. Table 2 il-
lustrates the themes and dimensions of youth’s perspectives on psychiatric med-
ications.
Effects of medications: What medications do to me. We found that youth fre-
quently talked about medications in relation to their perceptions of the medica-
tion’s effects across four dimensions: (a) body, (b) feelings/mood, (c) thinking/
cognitive functions, and (d) relationships and/or daily functioning. Many partici-
pants had patterns of intermittent medication use and spoke about the differ-
ences they observed across these dimensions when they were on or off medica-
tions. Descriptions of medications as helpful were often presented in the context
of the differences youth observed when they were or were not taking medica-
tions. Young adults also spoke about their experiences across these dimensions
in both positive and negative ways.
Medications work on my body. Depictions of the physical effects of medication
included explanations of the way medications work in the body and reports of
physical effects. Some participants used biological or medical terms to present
their understanding of how medications work.
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Table 2
Youth Perspectives on Psychiatric Medications: Themes and Dimensions
Theme Dimensions Exemplar quotation
Effects of medications
(n = 127 coded passages)
Body It balances the chemicals in my brain,
‘cause that’s what my mood disorder is,
my chemicals are off. [Participant #16]
Feelings/mood With medication it’s like I have mood
swings, but not as much, and I don’t
get angry as fast, or I don’t get sad as
fast. It’s like with the medication it
calms me. [Participant #11]
Thinking/
cognitive
Once I started getting back on the
medication I was able to make my
mind right and be able to think a little
bit further and figure out, plan ahead
and figure out what I can and cannot
do and what is more possible than
anything else. [Participant #15]
Functioning /
relationships
It’s like I don’t want to be around
people, I don’t want to talk to people,
but when I’m on my meds I’m able to




(n = 74 coded passages)
Psychiatrists
don’t understand
My med doctor doesn’t listen to me. They
don’t listen to what I want to do about
my meds and what meds I want to be on.
Like right now, I’m being put on some-




I just feel like she just wants to just put
me on all different type of medicine. I
just try to tell her some stuff. I don’t try
to tell her as much, because I just think
she think I’m just an experiment. Well, I
don’t just think [it’s just] her— I just
think a lot of doctors just, “Oh, you
should try this.” [Participant #7]
Relationship to
other treatments
Because I’m a talkative person and . . . I
dealt with my anger talking it out to
God or talking to myself. So that helps
me. It [counseling] soothes me better
than me popping a pill in my mouth. . . .
[Participant #20]
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They attack the central nervous system and they sedate it. They’re sedatives, you
know, and they calm you down . . . they stop like endorphins from flying around
your brain. (Participant #14)
Others described physical effects in personal terms, often in reference to adverse
effects:
When they put me on Ritalin, I got quiet and I did my work . . . but I didn’t eat
and my stomach was hurting constantly all the time. (Participant #35)
Medications change my moods. Many participants described medications as be-
ing helpful in controlling moods, especially anger and sadness: “With medication,
it’s like I have mood swings, but not as much, and I don’t get angry as fast or I don’t get
sad as fast” (Participant #11). However, these helpful effects were not without a
perceived cost in that several participants described the medication effects as
flattening their emotions: “Honestly, if I wanted to, I couldn’t force a tear. I can’t get
emotions to come out when I take my medications” (Participant #37). In some cases
this flattening contributed to participants’ decisions to reduce or stop the medi-
cations so that they could experience the full range of their emotions. For exam-
ple, one participant said,
I just felt like being depressed and letting the situation that was happening just go. I
didn’t really want to hide it or suppress it with the medication, so I just didn’t take
it. (Participant #26)
Medications change my thinking. Another perceived effect of medications was
their impact on thinking, which included improved focus and improved ability
to process and problem solve. One participant noted that with medication, “I was
able to make my mind right” (Participant #15), indicating that the effect of medica-
tions brought him closer to his perception of how his mind should function.
The perceived physical, emotional, and cognitive effects of medications also
had consequences for daily functioning. Participants noted the decision to not
take medication often had negative consequences such as problems with finding
and keeping a job and limited social interaction. For example;
I know when I don’t take them [medications] that there’s a big change in the way
that I . . . I don’t want to talk to people, but when I’m on my meds I’m able to deal
with being around people. (Participant #26)
Participants who were parents conveyed their mixed feelings about the positive
effects of medications on controlling their moods around their children but also
reported that adverse effects such as drowsiness had a negative impact on their
ability to be present for and attentive to their children.
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The different ways that medications affected participants across their bodies,
moods, thinking, and functioning were sometimes presented in relation to each
other. Some participants noted that when they felt they had greater control of their
emotions, they were able to think more clearly, which in turn, improved their
ability to work, to relate to others, and to be a parent. For example, one partici-
pant’s comment was typical of many: “If you’re screwed up emotionally, mentally you’re
going to be screwed up too. It works hand-in-hand” (Participant #15). In sum, partici-
pants’ perceptions of medications effects and how medications work across mul-
tiple dimensions demonstrated the ways in which young people made sense of
medication treatment and underscored that these perceptions were often formed
through their experiences of taking and not taking medications.
Getting medication treatment. The second theme identified in the interview data
was the process involved in getting medication treatment. Participants spoke of
their interactions with psychiatrists, the trial-and-error process of finding the
right medication and the right dosage of a medication, and they voiced concerns
about the quality of the treatment they had received. These comments provided
a sense of the contextual elements that shaped their perceptions of medication
treatment.
Psychiatrists don’t understand. Many participants commented about their interac-
tions with psychiatrists, especially interactions in which they did not feel the
psychiatrist was listening to what they were saying about their experiences.
These interactions were critical to both the young person’s experience of medi-
cation treatment and their assessment of treatment credibility. Most expressed
the feeling that psychiatrists did not respect them or listen to their perspectives:
. . . The med doctor . . . she just basically told me what’s good for me, what’s bad
for me and what I need to do . . . I’ve been on over 30 different medicines. . . .
I know what works, and she just treats me like a child. (Participant #24)
Psychiatrists’ lack of attention to their clients’ perspectives and experiences com-
bined with frequent medication changes contributed to the young adults’ nega-
tive perceptions of their psychiatrists. In contrast, a few participants described
positive treatment experiences characterized by a psychiatrist who listened at-
tentively to what the young person had to say:
[provider name] is the guy who gives me medication . . . I tell him how it makes
me feel, he doesn’t try to keep me on it and up the dose . . . he’s going to go ahead
and try other things. (Participant #32).
Participants also described frustrations resulting from a lack of continuity of
care. Those who saw several psychiatrists noted how receiving care from multi-
ple providers affected treatment:
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You talk to so many different psychiatrists, and they’re different people with differ-
ent views and different values and different you know everything. So you may seem,
you know, different to a different psychiatrist than you would to another psychia-
trist, you know, your diagnosis and everything else may be different. (Participant
#14).
Across participants, it was clear that young people valued providers who solic-
ited their perspectives and listened to what they had to say.
It’s just continuous trial and error. Medication treatment was described by several
young people as a trial-and-error process. Young people attributed this process
to the nature of mental disorders that are difficult to treat and the inability of
the doctor to precisely understand the patient’s experience. One young person
described this experience by saying,
If you’re a doctor and you’re working to make people feel better, you know you’ve
been sick before. . . . It’s totally different with mental disorders, because the other
person can’t tell how the other person is feeling, so it’s . . . just continuous trial and
error. (Participant #14)
For some, the trial-and-error process led to finding a medication that worked re-
liably:
They didn’t know exactly what my diagnosis was. There was a lot of trial and
error . . . when they found the right medication, they decided to stick to it. It’s
been my same medication for almost 4 years. (Participant #15).
Others described the difficulty that changing medication created: “They just be
changing my medicine. . . . I don’t like that. I like to be normal. Don’t have me all
discombobulated” (Participant #5). When young adults found the right medication
that worked, they talked about it with confidence, “They asked me what I would
take and I said ‘Nothing, other than Abilify. (Participant #57), and even fondness, “I
started taking my old Geodon and I feel so much better” (Participant #36).
In addition, some questioned the trial-and-error practice of polypharmacy,
and some young people wondered about the motivations of psychiatrists: “I feel
I was a guinea pig. They tried me with everything that came out” (Participant #7); and
“You know, a new drug comes on the market and the drug companies pay the doctors to
prescribe it to people” (Participant #14).
Medications and other treatments: They jump the gun straight to medication. Psychiatric
medications are just one type of treatment that can be used in conjunction with
other types of mental health services. Several participants talked about medica-
tions specifically in relation to other types of treatments, and stated their prefer-
ences for therapy instead of or in conjunction with medications. Many partici-
pants reported feeling that medications were prescribed too quickly: “I think that
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sometimes people kind of jump the gun straight to medication” (Participant #22). Others
expressed an opposing viewpoint, stating that with maintenance medications,
they had no need or desire for counseling: “I feel like I can do it on my own if I have
the medication. I don’t need the counseling, any of that” (Participant #36). Indeed, par-
ticipants expressed a variety of perspectives relative to their preferences for ther-
apy, medications, or a combination.
Stage 2: Narrative Analysis
The second stage in our analysis was guided by two questions: “Do young people
who have left public systems and are transitioning to adulthood create medica-
tion narratives to assist in making sense of their experiences of medication treat-
ment?”; and, if so, “Do these medication narratives help practitioners to better
understand the decisions and intentions of these young adults regarding medica-
tion use as they transition to adulthood?”
Within cases, we found evidence that young people do create medication
narratives that responded to three questions: (a) What is wrong with me that a
medication addresses? (b) What do the medications do to address the problem?;
and (c) What is the role of medications in my future? These elements were
instructive in understanding current medication use and provided insights into
the ways that participants thought of the role of medication in their future
lives. We specifically examined these narratives in relation to the young per-
son’s service use history and their outlook on future medication use to deter-
mine whether the medication narratives were instructive for developing a bet-
ter understanding of service use decisions generally. Through these analyses, we
noted prominent themes among young adults, including (a) the growing sense of
independence and maturity that shaped their attitudes toward taking medica-
tions, and (b) the role of illegal substances, which some presented as an alterna-
tive method of managing symptoms. In addition, these narratives assisted in un-
derstanding the contextual factors that shaped medication use and medication
use decisions.
To illustrate these factors, we have compiled case exemplars of the differing
attitudes and outlooks toward future medication use that we found across the
narratives. Through our analyses, three conceptually distinct outlooks emerged
that captured the narratives across these cases: committed to medication, ambiv-
alent toward medication, and no interest in medication.
Committed to Medication
Young adults whose narratives fell into this group were currently using medica-
tions, expressed the intention to continue, and had service use histories charac-
terized by either continuous use or a single gap in treatment. For those who had
experienced an interruption in service use, the time off medication was pre-
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sented as a break that helped the individual understand why he or she needed
medication. These young people tended to attribute their symptoms to biological
causes, and generally regarded mental health problems as a disease for which
treatment with medication was an appropriate and reasonable approach. These
participants generally had access to treatment, perceived their experiences with
medications as helpful, and had support systems that supported their commit-
ment to taking medications.
Case Example 1
Case 1 is a 19-year-old Caucasian male who is living in his grandmother’s home
and is currently taking Geodon. He first started taking psychotropic medications
for emotional and behavioral problems at age 13 years, and his history includes
involvement with publicly funded Medicaid mental health and child welfare sys-
tems. He was a resident in a group home until he aged out at 18 years old, and
moved to his grandmother’s house where he stopped taking medications. He at-
tributes this decision to a lack of a support system of people who would prompt
him to take medications and attend appointments.
He described significant anger problems that he characterized as “not normal”
and described his diagnosis of bipolar disorder as “a chemical imbalance” that is
long-term, requiring ongoing management. A central feature of his medication
narrative was his satisfaction with finding a medication that works for his symp-
toms. Before leaving the group home, he had come to understand that Geodon
was the right medication for him: “I was on a couple different pills . . . and I dropped
like 40 pounds in a month and a half . . . So he [physician] took me off of them, and I
realized that I needed them.” He had a prescription for Geodon, which he was able
to refill and resume his medication regimen. His story was also characterized by
his strong relationships with his girlfriend and his grandmother that he has main-
tained over the course of many years and many placements. Both his girlfriend
and his grandmother are supportive of his medication use.
With a support system in place and the recent experience of being off medi-
cation and then resuming medication, this young man reports a strong motiva-
tion to continue medication treatment. His outlook on his future use of medica-
tion appears to be shaped by his understanding of his symptoms as a medical
problem: “Just like some people who have asthma, they take their inhaler and their
medication for it. Same thing pretty much; just different situation.” He notes beneficial
effects of the medication, saying, “I don’t really feel like I’m bipolar now. Like with my
medicine, you know, I feel like a normal person.”
Ambivalent About Medication
Another type of medication narrative was characterized by ambivalence and an
uncertain outlook on the future. Young people in this category described not
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wanting or liking medication and reported feeling that medication did not work
for them. In several instances, the young person described using street drugs
instead of or in combination with their prescribed medications. Similar to those
who were committed to medication treatment, contextual factors contributed to
the ambivalent outlook, including lack of supportive others and a lack of prior
positive experiences in treatment. Case example #2 illustrates this ambivalent
outlook.
Case Example 2
Case 2 is a 19-year-old African American female living in her own apartment.
She is unemployed and is worried about what will happen with her housing
situation when her lease expires next month. She currently takes no medication,
but reported past use of Wellbutrin, Celexa, trazadone, Risperdal, and Seroquel.
She first started taking medications for emotional and behavioral problems at
age 13 years, and last took medication at age 18 years. Her history includes in-
volvement with publicly funded Medicaid mental health, child welfare, juvenile
justice, and the public welfare system. She aged out of the foster care system and
has become disengaged from services since leaving foster care, stating she does
not know the specifics of where or how to get services.
She describes her disorder as bipolar and her symptoms as extreme irritabil-
ity, but expresses ambivalence about the role of medications in treating her
symptoms. She noted that she has stopped taking the medications because of the
adverse effects but also expressed some positive opinions about medication:
I think for me it’s been good and bad, because I don’t feel like . . . The last medicine
I was on was that trazodone and I was always irritable, like even more so now. So,
the good thing is I’m not as irritable, but the bad thing is I don’t get much sleep, so
it’s like a good and a bad coming with it [being off medication].
Her treatment experiences during childhood while in the custody of the child
welfare system were not particularly positive and she noted that she did not like
that her care providers were “putting me on medicines that I really didn’t really want,
and if I didn’t take my medicine I got in trouble.” She reported an experience of
finding a medication she thought was effective but did not like the adverse ef-
fects: “I just didn’t like the fact that it made me eat . . . Seroquel was like the perfect
medicine, besides the weight thing.” One of her strategies for managing moods with-
out medications has been using marijuana, but she has not found that this drug
helps either.
She seemed to be actively searching for a solution that would help manage
her moods, and reported receiving strong support from a sister and her girl-
friend. Her hopes for treatment in the future centered on finding some type of
formal treatment that worked to manage her symptoms. She concluded the
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interview with a summary of her hopes for treatment: “I just really want a thera-
pist, a psychiatrist, and to figure out what med is right for me.”
No Interest in Medication
The third type of medication narrative—in which participants expressed no in-
terest in continuing medications—was less prominent in our sample. Only one
young person among the more densely coded cases had discontinued use of medi-
cations and stated no intention to resume using medication. He stated that he
thought his problems had been more developmental than organic, and his inten-
tion to remain off of medications was in line with this belief. He identified hav-
ing a support network that supported this decision as well as coping skills that
helped him in dealing with everyday problems.
Case Example 3
Case 3 is a 20-year-old African American male who is living with a friend. He
currently takes no medication, but reports having taken Ritalin, Concerta, Dex-
edrine, and Zoloft in the past. He first started taking psychotropic medication
for emotional and behavioral problems at age 10 years, and took medication
continuously from ages 10 to 14 years. His history includes involvement with
publicly funded Medicaid mental health services, child welfare, special educa-
tion, and juvenile justice systems. He has not used any mental health services
since turning 18, and reported feeling that he has “grown out” of many of the
problems that led him to service use during adolescence. He describes the
developmental process that he attributes as the reason for his improved men-
tal health status:
I feel it [mental health problems] stopped because I feel I have people I could talk
to and I could let my feelings out, ‘cause I used to just hold my feelings in and when
I would get angry, just all explode at one time, but now that I’ve matured and I’m
more comfortable with talking to people . . . I can express my feelings to people.
He reports having a girlfriend and friends he can talk to as well as alternate
coping skills such as playing basketball and listening to music.
His experiences in taking medication during his adolescence shaped his de-
sire to discontinue that form of treatment when he got older: “I felt like my mom
was just, my parents were just sending me to therapy as an escape and then using the
medicines as an escape just ‘cause they didn’t know how to deal with me.” He attributes
the cause of his problems to spending a substantial amount of time alone,
having no one to talk to, and not knowing how to express himself. As he grew
older, he learned new skills that addressed the problems that he perceived
caused his former difficulties. He commented that his current difficulties were
not “bad to where I need to go to a professional.” His key support comes from his
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mother; although she encouraged him to get medication during childhood, she
now supports his decision not to use services.
Discussion
This study assists in developing a better understanding of the medication per-
spectives of young adults who are transitioning to adulthood, and presents a
unique analysis that is focused on young people with mood and emotional chal-
lenges who have been involved in public systems. Several key findings emerged
that offer implications for practitioners who are seeking to support young adults
who are trying to make sense of their medication treatment.
First, across both the thematic and narrative analyses, we found that a devel-
opmental approach to medication perspectives is fundamental. We identified
four dimensions of medication effects that young people used to explain how
they experienced medications; these dimensions are similar to those identified
in prior research with both adolescents (Floersch et al., 2009) and adults (Bentley,
2010). Such research with adolescents has shown that families and peers play a
significant role in shaping the young person’s attitudes toward medications
(Floersch et al., 2009), whereas in work with adults, Bentley (2010) found that
medication use was “primarily an internal and individual experience” (p. 490).
The statements of participants in our study were consistent with an individual-
ized view in which young adults talked about their symptoms and their experi-
ences with medication effects. However, the narratives also showed the impor-
tance of supportive others in relation to these views. As adolescents become
young adults, they take on a different relationship with the medication, much as
they take on a different relationship with their primary support system and the
social service system. With increased autonomy, young adults need to develop
their own investment in their service use narrative; in other words, this narrative
must gradually become an internalized, individual experience that supports the
treatment decisions they make. To have it otherwise would mean the young adult
would forever remain dependent on external others to monitor and supervise
medication or other mental health treatment. In short, the experience of taking
medications involves more than a daily routine of “take this pill.” Young adults
talked about how the medications affected them in both positive and negative
ways and across multiple dimensions; they described how these myriad effects
contributed to their decisions to continue or discontinue medication as they took
control over their treatment.
A second key finding was the importance of treatment experiences in shaping
medication perspectives. Young people spoke of enduring a trial-and-error pro-
cess in getting medications, but interpreted this process in different ways, which
tended to be heavily influenced by their success in finding an effective medica-
tion. Making sense of this process was likely a direct result of what others have
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described as the gap between the hoped for and the actual effects of the medica-
tion (Longhofer, Floersch, & Okypch, 2011). When young people found what
they considered to be the right medication, they usually provided more positive
comments about the trial-and-error process. For those who had yet to find the
right medication, the trial-and-error process was often appraised negatively; they
expressed frustration and reported feeling like a guinea pig. Psychiatrists and
mental health professionals who support young adults through treatment need
to be clear at the outset about the trial-and-error nature of psychiatric medica-
tion treatment. Ongoing discussions could assist young adults in managing this
gap between the hoped for and the actual effects of their medication treatment,
and potentially lead to greater investment in following treatment recommenda-
tions and problem solving when a medication does not work.
Participants also noted interactions with psychiatrists as a significant part of
the experience of medication treatment. This finding is in line with prior re-
search that has noted a positive association between a patient’s trust in a pro-
vider and a patient’s positive attitudes toward medication treatment (Davis-
Berman & Pestello, 2008; Laurier, Lafortune, & Collin, 2010). Unfortunately, the
current structure of treatment which allows psychiatrists only limited time with
their patients likely contributes to a lack of trust in providers. A recent study with
young adults found a key facilitator to their treatment participation was the avail-
ability of their psychiatrist (Delman, Clark, Eisen, & Parker 2014). The young
adults in our study had much to offer as historians and as experts on their men-
tal health; their views were in line with several recent studies that found young
people want to be involved in collaborative approaches to treatment (Delman
et al., 2014; Simmons, Hetrick, & Jorm, 2011). Approaches that facilitate mutual
engagement of young people and psychiatrists in determining treatment such
as shared decision making could assist in improving satisfaction and follow-
through with treatment recommendations (Drake, Deegan, & Rapp, 2010). The
components of the medication narrative we identified in this study may provide
a foundation for shared decision making. Soliciting the young adults’ views on
the symptoms and diagnoses the medication is intended to treat, the medica-
tion effects, and the potential role of medications in the future provides a frame-
work for dialogue and the open communication necessary for shared decision
making.
As providers engage in these conversations with young people, it will be
important to maintain a value-neutral approach that focuses on simply under-
standing the young person’s medication narrative. In the current study, those
who were committed to continuing medication treatment often attributed their
symptoms to a biological cause such as a chemical imbalance. The biochemical
perspective was widely promoted when psychiatric medications became popular
in the early 1990s (Whitaker, 2005); however, the biological mechanisms that
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result in mental health symptoms are still poorly understood (U.S. Department
of Health and Human Services, 1999) and it is not clear that chemical imbal-
ances are the cause of mental health disorders. Those who experience symptom
relief might decide that if a medication is working, then there must be a biologi-
cal explanation (Cohen & Hughes, 2011) rather than starting with the belief in
an underlying chemical imbalance. The biological explanation provides insight
into how young adults may make sense of their experience, but this explanation
should not be regarded as the correct explanation or superior to other explana-
tions: it is simply the internalized narrative that some youth have come to own.
Another finding of our study was that participants often described coming
to an understanding of their need for medication through comparisons of their
symptoms when on and off the medications. However, psychiatric medications
produce changes in the brain that may result in withdrawal symptoms when
medications are abruptly discontinued (Whitaker, 2005); therefore, the experi-
ences of exacerbated symptoms when medications were suddenly stopped might
also be an iatrogenic effect of the medication treatment. This possibility also un-
derscores the importance of privileging the young person’s internalized medica-
tion service use narrative before complicating that narrative with external (e.g.,
psychiatry, social worker, parent, peer, teacher) medication narratives. Ideally,
through understanding perspectives and narratives about medications, providers
can deliver mental health treatments that make sense to the young people who
receive those interventions.
Strengths and Limitations
Our study presents perspectives on medication use from a unique group of young
adults with histories of formal diagnoses of mood disorders. Because it is a quali-
tative sample recruited using purposive sampling in one state, the results are not
generalizable to all young people who have transitioned out of systems of care
and/or have received a diagnosis of a mood disorder. Moreover, our study sample
was a specific subset of young people who had histories of medication use and
current indication of mental health need, and did not include the experiences of
young people who took medications while in systems but who have had no men-
tal health problems since leaving care. The interview guide was designed to elicit
narratives about mental health service use broadly, so questions were not specific
to medications. As such, the study findings might be biased toward presenting the
views of young people who felt strongly about their medication use. However, the
fact that young people presented their views about medication use within broader
narratives, could be considered a strength because the narratives contain reflec-
tions about medications relative to the individual’s everyday functioning and
transition to adulthood. A final limitation that should be considered in interpret-
ing the comments made by these young people is the effect of psychiatric medica-
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tion treatment itself. Psychiatric medications affect the brain and have been docu-
mented to produce significant changes in mood and attention (Healy & Farquhar,
1998), which might have influenced the type and quality of the information
provided by young people taking these medications.
Conclusion
Young adults who have exited public systems of care with mood and emotional
challenges are a particularly vulnerable group with high needs and limited re-
sources. This study provides insight into their perspectives on psychiatric medica-
tion and suggests some potential avenues for improving interventions. The find-
ings highlight the need to use a developmental approach in supporting young
adults’ decisions about treatments, which has been discussed as being increas-
ingly influenced by the attitudes toward and perceptions of illness held by the
young adults (Munson et al., 2009). Clinicians can play a key role in helping
young people to understand the trial-and-error process of medication treatment
and to help find a treatment that works for and makes sense to them. Models
such as shared decision making can promote an atmosphere in which young
people work in greater partnership with their psychiatrists, and thereby feel re-
spected, listened to, and involved in their treatment. Approaches that honor
young adults’ thoughts and emotions and engage them in making sense of their
treatment, hold promise for promoting greater engagement and enhancing self-
determination.
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